PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Introduction Intratumoral administration of pexa-vec (Pexastimogene Devacirepvec), an oncolytic and immunotherapeutic vaccinia virus. given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses. We hypothesized subsequent treatment with sorafenib...
Main Authors: | Ghassan K. Abou-Alfa, Peter R. Galle, Yee Chao, Joseph Erinjeri, Jeong Heo, Mitesh J. Borad, Angelo Luca, James Burke, Adina Pelusio, Delphine Agathon, Monika Lusky, Caroline Breitbach, Shukui Qin, Edward Gane |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2023-09-01
|
Series: | Liver Cancer |
Online Access: | https://beta.karger.com/Article/FullText/533650 |
Similar Items
-
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
by: Stephen M Hewitt, et al.
Published: (2023-02-01) -
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
by: Sophie Cousin, et al.
Published: (2022-12-01) -
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
by: Maud Toulmonde, et al.
Published: (2022-10-01) -
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide
by: Maud Toulmonde, et al.
Published: (2024-02-01) -
Konversi Format Data Phocus Ke dalam Format ARC/Info dan Autocad
by: Perpustakaan UGM, i-lib
Published: (1996)